Abstract

Objectives: To characterise spontaneous adverse drug reactions (ADRs) reported in the former German Democratic Republic (GDR) and to identify ADRs related to quality problems with pharmaceuticals. Material and methods: In 1964 a spontaneous ADR reporting system was established in the GDR with the purpose to collect information about possible toxic and damaging ADRs from medicine use. The spontaneous reporting system was also seen as an important tool for securing the quality of the pharmaceutical production. Data on ADRs occurring in the GDR were located in the national German archive, Bundesarchive in Berlin. Only ADR reports submitted from 1982 to 1990 were identified. The reports were analysed with respect to type of ADR (System Organ Class [SOC]) and substance. Results: From 1982 to 1990 a total of 3990 ADR reports covering information about 6706 ADRs were submitted to the GDR health authorities. The largest share, 26% of all ADRs referred to the SOC “ skin and subcutaneous disorders ”, followed by the SOCs “ general disorders and administration site conditions ” (23% of total ADRs) and “ gastrointestinal disorders ” (11% of total ADRs). Two-thirds of all ADRs were related to the therapeutic groups: “ anti- infectives for socs use” (ATC group J) and “ blood and blood forming organs” (ATC group B). Approximately 85% of ADRs from ATC group B was reported for dextran 40, the majority of these ADRs of the general type, followed by skin ADRs and ADRs concerning respiratory disorders. Additionally a high number of circulatory collapse/shock were reported for dextran 40. The increased level of ADR reporting was related to an abnormal distribution of low and high molecules of dextran 40 occurring due to production problems. Fifteen percent of ADRs were reported for radiographic contrast media; the majority for the substance amidotrizoate, and more than one half of these were of the type skin and respiratory disorders. Conclusion: In the GDR during the 1980s, the spontaneous ADR reporting system managed to detect serious pharmaceutical quality problems in dextran products. The products of lower quality could not be replaced easily due to lack of safer national alternatives as well as lack of foreign currency necessary to import of purer products from Western countries.

Highlights

  • The German Democratic Republic (GDR) (1949 to 1990) was known for its well developed pharmaceutical industry organized in state-owned companies that produced several pharmaceuticals, both original as well as generic products [1]

  • From 1982 to 1990 a total of 3990 adverse drug reactions (ADRs) reports covering information about 6706 ADRs were submitted to the GDR health authorities

  • The increased level of ADR reporting was related to an abnormal distribution of low and high molecules of dextran 40 occurring due to production problems

Read more

Summary

Introduction

The German Democratic Republic (GDR) (1949 to 1990) was known for its well developed pharmaceutical industry organized in state-owned companies that produced several pharmaceuticals, both original as well as generic products [1]. The generics were copies of pharmaceuticals already marketed 3 to 5 years previously in western countries and had to follow the international patent law [2]. From 1951 to 1989 a total of 48 original products were developed by the GDR pharmaceutical industry, e.g. the anabolic steroid chlordehydromethyltestosteron (Oral-Turinabol®) and the beta-blocker talinolol (Cordanum®) [1]. Despite the difficult financial situation after World War II innovative product development increased in the 1960s and 1970s resulting in an expansion of the GDR pharmaceutical industry [3].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call